Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Apply
Pembrolizumab & Bevacizumab
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step